📅 PUBMED DAILY TRIAGE — 2026-06-14 (Sunday)
Window: 2026-06-13T09:00:00Z → 2026-06-14T09:00:00Z (CRDT) Topics scanned: 9 | Articles reviewed: ~93 (incl. 2 deferred + sentinel top 10) | Formally classified: 21 High priority: 1 | Standard: 19 | Low/archive: 10+ | Unsolicited finds: 0 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Early Cancer Detection / Liquid Biopsy (T3) + CBC/ML (T2) + AI/ML Diagnostics (T4)
TR-2026-06-14-001 / PMID 42286706 · Circulating DNA reveals nucleosome occupancy patterns that are associated with nucleosome-DNA affinity and are affected in cancer · 8/10 🔴 → ML model on cfDNA nucleosome occupancy patterns hits >0.95 sensitivity/specificity for 7 cancer types in a pan-cancer liquid biopsy framework. Published in Genome Medicine. Uses FinaleDB public cohort; bioinformatics reanalysis — prospective validation pending, but methodological advance is significant. Bridges cfDNA fragmentomics (T3), hematology ML (T2), and AI diagnostics (T4).
Hematologic Malignancies: No high-priority finds today (best candidate scored 7/10)
Precision Oncology: No high-priority finds today (best scored 7/10)
Novel Therapeutics: No high-priority finds today (best scored 7/10)
Cardiovascular-Metabolic: No high-priority finds today (best scored 7/10)
Aging/Longevity: No high-priority finds today (best scored 7/10, T7/T8 crossover)
Rare Diseases: No high-priority finds today (best scored 6/10)
🟢⚪ STANDARD (5-7) — Top by Topic
Hematologic Malignancies (T1)
- TR-2026-06-14-002 / PMID 42287116 · Odronextamab bispecific antibody for follicular lymphoma · 7/10 · Treatment Innovation | Odronextamab (CD20xCD3) EMA-approved; Phase III OLYMPIA-1/2/5 frontline studies ongoing.
- TR-2026-06-14-007 / PMID 42286874 · IFITM1 insulin signaling promotes MM progression and bortezomib resistance · 6/10 · Drug Development | Novel MM resistance mechanism; prognostic biomarker vs. MGUS/SMM.
- TR-2026-06-14-006 / PMID 42287018 · NHL fertility outcomes meta-analysis (n=51 studies) · 6/10 · Prevention | First dedicated meta-analysis; 27% overall infertility prevalence, 35% male.
CBC-based Diagnostics / ML (T2)
- TR-2026-06-14-010 / PMID 42286617 · ARCHES RCT protocol: AI-guided intensive BP treatment in high-risk ICH · 5/10 · Diagnostics | Protocol only (n=680 planned); AI scoring of haematoma expansion risk enables RCT enrichment.
Early Cancer Detection / Liquid Biopsy (T3)
- TR-2026-06-14-011 / PMID 42286649 · Circular RNAs in tumor biology and immunology (Mol Cancer review) · 5/10 · Early Detection | circRNA as emerging stable cfDNA-complementary liquid biopsy biomarker class.
AI/ML in Clinical Diagnostics (T4)
- TR-2026-06-14-008 / PMID 42286892 · AI+CGM digital health platform associated with clinically significant weight loss n=3007 · 6/10 · Prevention | Engaged periods yielded 2.7x greater weekly weight loss; Diabetes Technol Ther.
- TR-2026-06-14-018 / PMID 42286973 · DUAG deep learning reconstruction for low-field MRI · 5/10 · Diagnostics | Improves affordable 0.3-0.5T MRI quality; potential impact in resource-limited settings.
- TR-2026-06-14-010 / PMID 42286617 · (see T2 above)
Precision Oncology / Genomics (T5)
- TR-2026-06-14-004 / PMID 42286715 · Q40 sequencing benchmarking for rare somatic variant detection (Genome Biology) · 7/10 · Genomics | Q40 reduces required depth by 33%, improves low-VAF sensitivity by 33%, 6x better CNV reproducibility.
- TR-2026-06-14-005 / PMID 42286806 · H. pylori exposure in BRCA1/2/PALB2/ATM carriers n=1327 (Int J Cancer / Penn Basser) · 7/10 · Prevention | 17.4% Hp exposure rate in BRCA carriers; non-White race significantly associated.
- TR-2026-06-14-009 / PMID 42274032 · Dedifferentiated liposarcoma real-world outcomes n=123 US community (Cancer Med) · 6/10 · Treatment Innovation | MDM2 testing 78%; metastatic rwOS 11.7 months; MDM2/CDK4 unmet need confirmed.
- TR-2026-06-14-013 / PMID 42287052 · Perioperative hyperglycemia predicts ESCC survival n=5952 multicenter · 5/10 · Prevention | Combined peri-op hyperglycemia HR=1.86; actionable perioperative glucose control.
- TR-2026-06-14-012 / PMID 42286625 · Intestinal SMARCA4-DUC case series/review n=20 (World J Surg Oncol) · 5/10 · Treatment Innovation | 2/5 pembrolizumab CRs >18 months; molecular predictors needed.
Novel Therapeutics (T6)
- TR-2026-06-14-002 / PMID 42287116 · (Odronextamab FL — see T1)
- TR-2026-06-14-016 / PMID 42286765 · Cytokine network dual balance review (Biomark Res) · 5/10 · Treatment Innovation | Bispecific antibodies and CAR-T cytokine targeting strategies reviewed.
- TR-2026-06-14-017 / PMID 42287067 · NKG2D immune escape + radionuclide theranostics cervical cancer (scRNA-seq) · 5/10 · Treatment Innovation | MICA/MICB dysregulation mapped; NKG2D-directed probe targeting identified.
Cardiovascular-Metabolic (T7)
- TR-2026-06-14-003 / PMID 42287049 · Biological age (Light BioAge) for CVD risk prediction n=226,406 Chinese cohort · 7/10 · Diagnostics | AgeDiff predicts CVD +21-27%; biological age in WHO model reduces women's 20.5% overestimation.
- TR-2026-06-14-008 / PMID 42286892 · (AI+CGM obesity — see T4)
- TR-2026-06-14-014 / PMID 42286992 · Oral semaglutide obesity guidance with OASIS 4 data (Postgrad Med) · 5/10 · Treatment Innovation | Practice guide for recently approved oral GLP-1 obesity indication.
- TR-2026-06-14-015 / PMID 42286858 · Eating habits + ischemic stroke Mendelian randomization study · 5/10 · Prevention | Cheese (OR 0.70), dried fruit (OR 0.57), muesli (OR 0.20) protective vs. stroke.
Aging / Longevity (T8)
- TR-2026-06-14-003 / PMID 42287049 · (Biological age + CVD — see T7)
- TR-2026-06-14-019 / PMID 42286837 · Microbiome dynamics review across health and disease lifespan (Gut Microbes) · 4/10 · Prevention | Broad synthesis including aging-relevant dysbiosis; FMT and engineered microbiome strategies reviewed.
Rare Diseases (T9)
- TR-2026-06-14-009 / PMID 42274032 · (DDLPS real-world — see T5)
- TR-2026-06-14-012 / PMID 42286625 · (SMARCA4-DUC — see T5)
- TR-2026-06-14-020 / PMID 42286918 · SMA history: gene discovery to approved therapies (J Child Neurol review) · 4/10 · Treatment Innovation | Access equity for nusinersen/onasemnogene/risdiplam globally is the primary challenge.
💡 UNSOLICITED FINDS
None — all high-signal sentinel scan top-10 candidates were already captured by watchlist queries.
📊 TODAY'S BREAKDOWN
By research category:
- Early Detection: 2 (incl. 1 HIGH)
- Treatment Innovation: 8
- Prevention: 6
- Diagnostics: 4
- Genomics/Precision Medicine: 1
- Drug Development: 1
- Public Health: 2
By evidence maturity:
- Exploratory: 12
- Validated: 7
- Potentially Practice-Changing: 0
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | Best |
|---|---|---|---|
| T1 Hematologic malignancies | 10 | 3 | 7 (PMID 42287116) |
| T2 CBC/ML | 2 | 2 | 8 (PMID 42286706) |
| T3 Liquid biopsy/ctDNA | 3 | 2 | 8 (PMID 42286706) |
| T4 AI/ML diagnostics | 10 | 3 | 8 (PMID 42286706) |
| T5 Precision oncology | 7 | 5 | 7 (PMID 42286715) |
| T6 Novel therapeutics | 10 | 3 | 7 (PMID 42287116) |
| T7 Cardiovascular-metabolic | 10 | 4 | 7 (PMID 42287049) |
| T8 Aging/longevity | 4 | 2 | 7 (PMID 42287049) |
| T9 Rare diseases | 3 | 3 | 6 (PMID 42274032) |
| Sentinel | 10 | 0 | — |
| Deferred (06-12) | 2 | 1 | 6 (PMID 42274032) |
By source type: peer_reviewed 21 | preprint 0
Topics with zero 8+ articles this run: T1, T5, T6, T7, T8, T9
🔧 RUN NOTES
- Deferred PMIDs cleared: Both 42274988 and 42274032 from the 2026-06-12 carry-forward were resolved. PMID 42274988 (pediatric IBD review, Paediatric Drugs) scored 4/10 and was discarded as off-core-watchlist. PMID 42274032 (DDLPS real-world outcomes, Cancer Med) scored 6/10 and was formally classified as TR-2026-06-14-009 (T5/T9). No remaining deferred PMIDs.
- Sentinel scan: 119 raw results retrieved; top 10 reviewed. All high-signal candidates were already captured by watchlist-specific queries. No new unsolicited finds.
- T2 (CBC/ML) low volume: Only 2 raw results again. The topic's best article (42286706) was a cfDNA/ML study, not strictly CBC. This query continues to underperform; a broader reformulation incorporating "blood-based" and "hematology" may improve yield.
- T7 zero-HIGH streak: Day 3 in a row. Today's best T7 article (PMID 42287049, biological age for CVD, 7/10) is promising but STANDARD. The GLP-1/SGLT2 landscape is producing numerous guidance/review articles rather than high-impact primary data this week.
- T8 zero-HIGH streak: Day 4+ in a row. Best T8 article today shares with T7 (PMID 42287049, biological age). The humans[MeSH] filter is performing as intended — no animal biology noise in results.
- No truncation events: All topic caps (10 per topic) respected; no topic hit cap requiring additional pagination.
- Excluded articles: 2 editorials/comments excluded (PMID 42286900 editorial, PMID 42287026 comment/reply); 2 off-watchlist articles excluded (PMID 42286957 probiotics/allergy, PMID 42286953 pediatric anaphylaxis).
- Rolling 7-day zero-HIGH topics: T7 (zero-HIGH: 3 consecutive days); T8 (zero-HIGH: 4+ consecutive days). Consideration: T7 query may benefit from adding RCT-specific terms to filter for primary data over reviews.